

September 25, 2014



Actinium to Present at the 14th Annual Biotech in Europe Forum for Global Partnering and Investment on September 30th

CMO to Participate in the Oncology II - Next Generation Immunotherapeutics Panel Discussion

NEW YORK, NY -- (Marketwired) -- 09/25/14 -- [Actinium Pharmaceuticals, Inc.](http://www.actiniumpharma.com) (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Dragan Cicic, Chief Medical Officer of Actinium will participate in the Oncology II - Next Generation Immunotherapeutics panel discussion on Tuesday, September 30, 2014 at 2:00pm as part of the 14th Annual Biotech in Europe Forum for Global Partnering and Investment held in Basel, Switzerland. In addition, the Company's Executive Chairman, Sandesh Seth, also in attendance, will give a corporate presentation on September 30th at 11:00am.

Dr. Cicic will join leading cancer experts from industry to discuss the increasing role of combination and targeted therapies in Oncology as well as provide a brief introduction of the potential clinical and therapeutic utility of Actimab-A and lomab™-B. The panel will also explore new emerging targets or approaches for immunotherapies and discuss which clinical strategies hold the most promise.

The Annual Biotech in Europe Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives.

Members of the investment community who are interested in meeting with management should contact Evan Smith, CFA of Actinium Pharmaceuticals at (646) 840-5442 or esmith@actiniumpharma.com.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal

antibodies. The Company's lead radiopharmaceutical lomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of lomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.

Evan Smith, CFA

VP Investor Relations and Finance

+1 (646) 840-5442

Email: esmith@actiniumpharma.com

Source: Actinium Pharmaceuticals